CACNG4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL116362	0.45	11/20
SCHEMBL6121858	0.52	9/20
SCHEMBL2585915	0.51	8/20
SCHEMBL3354274	0.62	7/20
SCHEMBL3357851	0.54	7/20
SCHEMBL4750473	0.52	7/20
SCHEMBL3350921	0.49	7/20
SCHEMBL619154	0.41	7/20
SCHEMBL620978	0.40	7/20
SCHEMBL621013	0.40	7/20
SCHEMBL5428566	0.52	6/20
SCHEMBL621555	0.39	6/20
SCHEMBL617973	0.38	6/20
SCHEMBL7053553	0.62	5/20
SCHEMBL4405461	0.55	5/20
SCHEMBL4399845	0.54	5/20
SCHEMBL4967687	0.51	5/20
SCHEMBL1810921	0.51	5/20
SCHEMBL4399843	0.50	5/20
SCHEMBL3477582	0.47	5/20

Clinical trials — most relevant to CACNG4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination	PHASE4	UNKNOWN
Role of Intralipid in Management of Organophosphorus Poisoning	PHASE2/PHASE3	WITHDRAWN
Pain and Chronic Pancreatitis - Clinical End Experimental Studies	PHASE2/PHASE3	COMPLETED
The Re-Prosper HF Study	PHASE2/PHASE3	COMPLETED
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients	PHASE2	WITHDRAWN
Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain	PHASE2	COMPLETED
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients	PHASE2	WITHDRAWN
A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome	PHASE1/PHASE2	NOT_YET_RECRUITING
Effect of Lidocaine Transdermal Patch as Add-On Therapy in Treatment of Oxaliplatin Induced Peripheral Neuropathy in Colorectal Cancer Patients	PHASE2	UNKNOWN
Physiologic Effects of Topiramate on Cognition	PHASE1	COMPLETED
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development	nan	RECRUITING
The Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) on Working Memory	nan	COMPLETED
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services	nan	UNKNOWN
Factors Affecting Salt Intake in Young Adults	nan	UNKNOWN
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases	nan	UNKNOWN
Characterization and Functionality of Calcium Channels Cav1.4 of Th17 Lymphocytes in Human With Psoriasis	nan	COMPLETED
The Natural History of TRPV4 Neuropathy	nan	RECRUITING
iCorMicA - Stratified Medicine in Angina	nan	RECRUITING
Pregabalin Phonophoresis and MET for Knee Osteoarthritis	nan	RECRUITING
Sodium Channel Splicing in Heart Failure Trial	nan	COMPLETED
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study	nan	UNKNOWN
A Single Center Prospective Study in an Estimated 570 Patients Who Underwent Genetic Screening at UZ Brussel in the Context of a Primary Cardiac Arrhythmia. Patients Showing a Variant Class 3,4 or 5 in SCN4A or CLCN1 Will Undergo a Clinical and Electrophysiological Review After IC.	nan	NOT_YET_RECRUITING
ST-segment Elevation as an AF Endophenotype	nan	COMPLETED
Multicenter Study of Patients With SHANK3 Mutations: Identification of Genes Modificators in Phelan-McDermid Syndrome (EUQ13)	nan	NOT_YET_RECRUITING
Pharmacogenetics and Cardiovascular Events	nan	COMPLETED
Neurogenic Mechanisms in Burning Mouth Syndrome	nan	COMPLETED
Neurogenetic And Hemodynamic Of Migraine Aura And Pfo	nan	RECRUITING
Exploring the Genetics of Neuropathic Pain	nan	RECRUITING
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CACNG4 binder may also engage these)

Protein	Name	Similarity
Q8VHW9	—	1.000	Q8VHW9 →
Q9JJV4	—	1.000	Q9JJV4 →
Q8VHX0	—	0.973	Q8VHX0 →
O88602	—	0.973	O88602 →
Q71RJ2	—	0.972	Q71RJ2 →
CACNG2	Voltage-dependent calcium channel gamma-2 sub	0.972	landscape →
CACNG3	Voltage-dependent calcium channel gamma-3 sub	0.971	landscape →
Q4R589	—	0.971	Q4R589 →
Q0VD05	—	0.971	Q0VD05 →
Q9JJV5	—	0.970	Q9JJV5 →
Q5R5X2	—	0.970	Q5R5X2 →
Q5VXT5	—	0.963	Q5VXT5 →
Q7TMP6	—	0.962	Q7TMP6 →
Q9BE63	—	0.962	Q9BE63 →
Q8BHW5	—	0.962	Q8BHW5 →
Q5JRV8	—	0.962	Q5JRV8 →
Q0VGY8	—	0.960	Q0VGY8 →
O13097	—	0.960	O13097 →
Q08CE6	—	0.959	Q08CE6 →
Q6F6B3	—	0.958	Q6F6B3 →
Q66IQ1	—	0.958	Q66IQ1 →
CACNG5	Voltage-dependent calcium channel gamma-5 sub	0.958	landscape →
Q5RH73	—	0.957	Q5RH73 →
KCNK13	Potassium channel subfamily K member 13	0.957	landscape →
Q4V922	—	0.956	Q4V922 →
D4A6L0	—	0.955	D4A6L0 →
Q9UQB3	—	0.955	Q9UQB3 →
Q4KUS2	—	0.955	Q4KUS2 →
Q5T848	—	0.955	Q5T848 →
E1BBQ2	—	0.955	E1BBQ2 →